Combining drugs and biologics to treat nasopharyngeal cancer

Molecular Therapy

Volumn 22, Issue 1, 2014, Pages 8-9

  Heslop, Helen E ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; DISEASE ASSOCIATION; DRUG RESPONSE; EPSTEIN BARR VIRUS; HUMAN; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; NASOPHARYNGEAL NEOPLASMS;

EID: 84891769522     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.272     Document Type: Note

References (16)

1. Restifo, NP, Dudley, ME and Rosenberg, SA (2012). Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 12: 269-281
2. Levine, BL and June, CH (2013). Perspective: Assembly line immunotherapy. Nature 498: S17
3. Bollard, CM, Rooney, CM and Heslop, HE (2012). T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9: 510-519
4. Brenner, MK, Gottschalk, S, Leen, AM and Vera, JF (2013). Is cancer gene therapy an empty suit? Lancet Oncol 14: E447-e456
5. Chia, W-K, Teo, M, Wang, W-W, Lee, B, Ang, S-F, Tai, W-M et al. (2014). Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22: 132-139
6. Young, LS and Rickinson, AB (2004). Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768
7. Martorelli, D, Houali, K, Caggiari, L, Vaccher, E, Barzan, L, Franchin, G et al. (2008). Spontaneous T-cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. Int J Cancer 123: 1100-1107
8. Comoli, P, Pedrazzoli, P, Maccario, R, Basso, S, Carminati, O, Labirio, M et al. (2005). Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23: 8942-8949
9. Louis, CU, Straathof, K, Bollard, CM, Ennamuri, S, Gerken, C, Lopez, TT et al. (2010). Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33: 983-990
10. Straathof, KC, Bollard, CM, Popat, U, Huls, MH, Lopez, T, Morriss, MC et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus- specific T lymphocytes. Blood 105: 1898-1904
11. Secondino, S, Zecca, M, Licitra, L, Gurrado, A, Schiavetto, I, Bossi, P et al. (2012). T-cell therapy for EBV-associated nasopharyngeal carcinoma: Preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol 23: 435-441
12. Louis, CU, Straathof, K, Bollard, CM, Gerken, C, Huls, MH, Gresik, MV et al. (2009). Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 113: 2442-2450
13. Ngo, M, Ando, J, Leen, AM et al. Complementation of antigen presenting cells to generate T lymphocytes with broad target specificity. J Immunother, in press
14. Smith, C, Tsang, J, Beagley, L, Chua, D, Lee, V, Li, V et al. (2012). Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72: 1116-1125
15. Heslop, H (2011). Getting personal with melanoma. Clin Cancer Res 17: 4189-4191
16. Byrd, JC, Furman, RR, Coutre, SE, Flinn, IW, Burger, JA, Blum, KA et al. (2013). Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369: 32-42